Sensorium embraces and decodes the complexities of human biology and nature to develop breakthrough medicines for people suffering from brain and mental health conditions.
Lead program in social anxiety disorder in Phase 1 trial
We discern patterns across eons of chemical evolution and millennia of knowledge with a mission to transform mental health and CNS treatment.
SensAI integrates natural compounds, human experience, pharmacology, and neuroscience across 50M+ relationships to identify therapeutic patterns screening-based approaches cannot systematically find.
Anxiety
SENS–01
Phase 1
Drug-resistant epilepsy + anxiety
SENS–03
Lead candidate
Anxiety
SENS–01
Phase 1
Drug-resistant epilepsy + anxiety
SENS–03
Lead candidate
For millennia, humans discovered which natural compounds heal the mind. Sensorium systematically explores these insights alongside chemistry and neuroscience to recover therapeutic opportunities modern discovery abandoned.
We’re translating patterns into precision therapeutics that may enrich human wellbeing and retrieve people from suffering.
Let’s talk
Nearly 85% of approved CNS drugs are derived from nature.
Our SensAI platform integrates 50M+ relationships across natural compounds, human experience, pharmacology, and neuroscience.
We have developed three programs in three years, each with novel MOAs.
SENS–01, our first-in-class precision anxiety therapy, is in the clinic. Novel serotonin modulator for social anxiety; rapid onset, reduced side effects; multi-indication potential (GAD, OCD, PTSD)
SENS–03 is our dual-action therapy for drug-resistant epilepsy and comorbid anxiety; development candidate selection 2H 2026
SENS–08 is our NIH-funded preclinical program for Alzheimer’s-related cognitive impairment
Sensorium Therapeutics is a clinical stage biotechnology company developing brain and mental health treatments that are derived from nature, mechanistically driven, clinically precise, and designed to help people thrive. Its proprietary SensAI™ platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience to unlock broader and derisked starting points for CNS drug discovery. SensAI has produced three differentiated programs in under three years—led by SENS-01, a first-in-class compound under investigation for the treatment of anxiety disorders—and built a robust IP estate extending into the 2040s.
© 2026 Sensorium Therapeutics.
All rights reserved.
FCOI policy
Privacy policy